We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Orqis Medical, developer of the catheter-based Cancion cardiac recovery system
(CRS) to treat congestive heart failure (CHF), announced FDA unconditional approval
for researchers to treat up to 200 CHF patients at 40 centers participating
in the company's MOMENTUM (Multicenter Trial of the Orqis Medical CRS for the
Enhanced Treatment of CHF, Unresponsive to Medical Therapy) pivotal clinical
trial.
Alcon announced the launch of the AcrySof ReSTOR Intraocular Lens (IOL) at a
press conference during the American Society of Cataract and Refractive Surgery
and the American Society of Ophthalmic Administrators Symposium in Washington,
D.C.
EP MedSystems and Royal Philips Electronics announced a multiplatform joint
development agreement, as a part of the companies' broad strategy to provide
the most technologically advanced products for the EP physician.
A painless, portable device that uses electrical current rather than X-ray to
examine breasts for cancer is under study at the Medical College of Georgia
(MCG).
Novoste faces delisting from the Nasdaq stock market because its stock has traded
below the $1 a share minimum requirement for 30 days in a row. Nasdaq will give
Norcross-based Novoste until Oct. 18 to regain compliance.
Analog Devices, maker of high-performance semiconductors for signal processing
applications, extended its leadership in analog signal processing technology
with an integrated circuit that simplifies the development of continuous wave
(CW) Doppler imaging in stationary and portable ultrasound systems.
Caliper Life Sciences and Affymetrix announced that Caliper has issued Affymetrix
a nonexclusive license to use a portion of Caliper's microfluidics patent estate
with Affymetrix' GeneChip microarray technologies.
Misonix, a developer of ultrasonic medical device
technology for the treatment of cancer and other healthcare purposes, announced
that both the Sonablate 500 product used for the treatment of prostate cancer
and its FS1000 Neuroaspirator for soft tissue removal used primarily in neurosurgery
have received approval from the Russian Federation.
Nymox Pharmaceutical has been informed that its premarket approval (PMA) application
to the FDA concerning a kit version of the company's AlzheimAlert urine test
will be going forward to a presentation before a panel of the Medical Devices
Advisory Committee.